News | December 06, 2022
Briefs: Natco Pharma & Lupin
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
The service includes full fertility care benefits, including egg and embryo freezing options to employees
Asia’s premier and USA-patented, ANSSI Wellness for spinal decompression was launched in Pune
The new eye hospital in Vashi is ASG’s second in the Mumbai Metropolitan Region (MMR) and the sixth in Maharashtra
It offers quick relief in various types of Coughs, Colds and Sore Throat,
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Subscribe To Our Newsletter & Stay Updated
